Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Daniel Breadner
Unveiling the Synergistic Potential: Bispecific Antibodies in Conjunction with Chemotherapy for Advanced Non-Small-Cell Lung Cancer Treatment
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Implementation of Liquid Biopsy in Non-Small-Cell Lung Cancer: An Ontario Perspective
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
The Current Role of Radiation in the Management of Cholangiocarcinoma-A Narrative Review
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
An Updated Review of Management of Resectable Stage III NSCLC in the Era of Neoadjuvant Immunotherapy
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Real-World Analysis of Durvalumab after Chemoradiation in Stage III Non-Small-Cell Lung Cancer
1. Introduction Stage III non-small-cell lung cancer (NSCLC) represents a heterogeneous class of disease which continues to serve the oncology community a treatment quandary; often, such tumours are not resectable, yet the specifics of optimal multi-modality treatment remain elusive [1].
‘Targeting’ Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer—An Updated Review
1. Introduction Lung cancer is the second most common cancer worldwide and the leading cause of cancer-related deaths [1]. Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all new lung cancer cases and more than two-thirds are advanced/metastatic at the initial diagnosis. With the continuing advancements in the genomic underpinnings of lung cancer, it is now at the helm of personalized therapy.
Exploitation of treatment induced tumor lysis to enhance the sensitivity of ctDNA analysis: a first-in-human pilot study
Highlights • ctDNA levels increase in the hours to days after starting a new treatment. • Testing ctDNA in the hours after starting treatment increases sensitivity. • Testing hours after treatment may reveal mutations that were occult pre-treatment. Abstract Introduction Blood-based liquid biopsies examining circulating tumour DNA (ctDNA) have increasing applications in non-small cell lung cancer (NSCLC). Limitations in sensitivity remain a barrier to ctDNA replacing tissue-based testing.
Efficacy and safety of ALK inhibitors in ALK-rearranged non-small cell lung cancer: A systematic review and meta-analysis
To view the full text, please login as a subscribed user or purchase a subscription. Click here to view the full text on ScienceDirect. Fig. 1 Flowchart of study selection in the meta-analysis. Fig. 2 Forest plots for overall survival in the included randomized control trials (a) testing ALK inhibitors versus chemotherapy and (b) testing second-generation ALK inhibitors versus crizotinib. Highlights •ALK inhibitors prolong overall survival (OS) compared to chemotherapy in ALK + NSCLC.
Phase II trial of capecitabine plus erlotinib versus capecitabine alone in patients with advanced colorectal cancer
Aim & methods: Capecitabine monotherapy as palliation for advanced colorectal cancer (CRC) is generally well tolerated. Adding erlotinib, an EGFR-tyrosine kinase inhibitor, might improve efficacy versus capecitabine alone. 82 patients received capecitabine alone (Arm 1) or capecitabine with erlotinib (Arm 2). Results: Median time-to-progression (TTP) in Arm 1 was 7.9 months versus 9.2 in Arm 2. In KRAS-wild type (WT) patients TTP was 8.4 and 11.7 months in Arms 1 and 2, respectively.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Daniel
Contact Daniel, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack